Lakewood-Amedex Backs PASTEUR Act, Eyes Phase 2 Launch for Nu-3 Diabetic Foot Ulcer Therapy
LABT•Lakewood-Amedex Biotherapeutics endorses the bipartisan PASTEUR Act to accelerate funding for novel antimicrobials and spotlights its Bisphosphocin® class, which shows rapid in vitro killing of MRSA and VRE with low resistance potential. The company is preparing to initiate Phase 2 trials of topical Nu-3 for infected diabetic foot ulcers.
1. Legislative Support for PASTEUR Act
Lakewood-Amedex has publicly supported the reintroduction of the bipartisan Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act, which proposes subscription-style payments to incentivize development of new antimicrobial therapies. This legislation aims to address global antimicrobial resistance (AMR) by providing predictable revenues for companies that bring novel antibiotics to market.
2. Bisphosphocin® Platform and Resistance Profile
The company’s proprietary Bisphosphocin® class exhibits rapid, concentration-dependent disruption of bacterial cell membranes, demonstrating high in vitro activity against antibiotic-resistant strains, including MRSA and VRE. Initial resistance development studies suggest a lower likelihood of target organisms developing resistance to Bisphosphocin® compounds compared with traditional antibiotics.
3. Advancement of Nu-3 into Phase 2 Trials
Lakewood-Amedex is preparing to enter Phase 2 clinical development with its lead candidate, Nu-3, as a topical treatment for infected diabetic foot ulcers (iDFUs). iDFUs affect millions globally and often lead to severe complications; Nu-3’s fast-acting, broad-spectrum profile is intended to address this unmet need and reduce hospitalizations and amputations.
